|
Feb 24, 2026
|
Nakayama, C., Fang, Q., Daigaku, Y., Aoi, Y., Ito, S., Takahashi, M., Shimatani, R., Minamisawa, T., Ozturk, Y., Kimura, H., Shilatifard, A., Tellier, M. and Nojima, T. NELF prevents transcriptional readthrough into DNA replication zones in cancer cells.
EMBO Rep., in press (2026)
|
|
Feb 13, 2026
|
Tanaka, Y., Sakahara, M., Yamanaka, H., Natsume, Y., Kusama, D., Kumegawa, K., Yoshikawa, H., Abe, Y., Okabayashi, K., Matui, S., Kitagawa, Y., Koshikawa, N., Osumi, H., Shinozaki, E., Nagayama, S., Adachi, J., Maruyama, R. and Yao, R. Ribosome biogenesis as a potential therapeutic target in KRAS mutant colorectal cancer.
Nat. Commun., 17, 1224 (2026)
|
|
Feb 09, 2026
|
Thanongsak, W., Kawahara, M., Nakamoto, M., Homma, K., Sereemaspun, A., Tachaboonyakiat, W., Ruktanonchai, U., Yoshimoto, K., Katayama, R., Matsusaki, M. and Chirachanchai, S. Concerted pH-responsive performance of chitosan-deoxycholic acid as a polymeric molecular block for cancer cell disruption.
ChemMedChem, 21, e202500587 (2026)
|
|
Feb 09, 2026
|
Izumi, H., Sakamoto, T., Uchibori, K., Nishino, K., Sakakibara-Konishi, J., Katayama, R., Nomura, S., Matsumoto, S., Udagawa, H., Shibata, Y., Sakai, T., Nosaki, K., Zenke, Y., Yoh, K., Niho, S. and Goto, K. Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutation.
Cancer Treat. Res. Commun., 46, 101105 (2026)
|
|
Jan 30, 2026
|
Wakita, M., Ito, K., Fujii, K., Sakamoto, D., Mikawa, T., Sugawara, S., Zhou, X., Park, J. H., Miyagawa, H., Motooka, D., Ogasawara, E., Ishihara, N., Takahashi, A., Kondoh, H. and Hara, E. Comparative analysis of senolytic drugs reveals mitochondrial determinants of efficacy and resistance.
Nature aging, in press (2026)
|
|
Jan 13, 2026
|
FuKoichi, J., Kitamura, K., Kawahara, R., Shihoya, W., Nureki, O., Hosoya, S., Nakagawa, R., Mashima, T., Itoh, H., Inoue, M. and Sakurai, K. Photoaffinity labeling strategy reveals tetraspanin CD9 as a transient target of anticancer Yaku’amide B.
J. Am. Chem. Soc., in press (2026)
|
|
Jan 13, 2026
|
Moroishi, K., Nakamoto, M., Fujita, S., Kawahara, M., Katayama, R. and Matsusaki, M. Escape from cell uptake: Drug-free cancer therapeutics regulated by hydrophobicity and negative charge.
Mater. Today Bio, 102752 (2025)
|
|
Jan 05, 2026
|
Otsuka, M., Okamoto, Y., Hasebe, A., Shirahama, H. and Tomida, A. HER3 enhances ATF4 induction and survival in breast cancer cells during endoplasmic reticulum stress.
Biochem. Biophys. Res. Commun., 797, 153215 (2026)
|
|
Jan 05, 2026
|
Yokomura, M., Nagano, S., Kawamoto, H., Hirohashi, Y., Torigoe, T., Asakage, T. and Katayama, R. Afatinib exerts an inhibitory effect on T cell-mediated cytotoxicity.
Cancer Immunol. Immunother., 75, 33 (2026)
|
